Dr. Leigh Zawel is the CSO of Small Molecules for Cullinan Oncology (NASDAQ: CGEM), a portfolio company of the UBS Oncology Impact Fund managed by MPM. Leigh is an oncology expert with significant pharmaceutical experience overseeing large and small-molecule projects He is also a Board Member of Rekindle Therapeutics, an MPM Capital portfolio company.
Prior to joining MPM, Leigh was Vice President and East Coast Site Head for Pfizer’s Centers for Therapeutic Innovation where he managed a portfolio of large and small-molecule projects spanning oncology, immunology and rare disease from which five clinical stage programs emerged in five years. Prior to Pfizer, he was the oncology site lead at Merck Research Laboratories in Boston. In this role, he was responsible for drug discovery efforts focused on the identification of development candidates for programs in the oncology franchise. He also formerly held posts at Sanofi-Aventis, where he was Director of Cancer Biology, and at Novartis Institutes for Biomedical Research, where he was an Oncology Group Leader and led the team credited with discovering LCL161, an industry leading IAP inhibitor. He has a deep background in identifying and validating oncology drug targets and in transitioning drug discovery programs through lead optimization to Phase 1 clinical trials. Leigh has published more than 35 scientific papers. He is also an inventor on 45 patents covering chemical matter, drug combinations, biomarker utility and gene function in areas of apoptosis, inflammation and TGFB signaling.
Leigh earned his Ph.D. in the laboratory of Danny Reinberg where he identified and characterized components of the RNA Polymerase II basal transcription machinery. His postdoctoral training was in the laboratory of Bert Vogelstein and Ken Kinzler and focused on dysregulation of TGFB signaling in cancer. Leigh also holds a M.S. in Bacteriology from the University of Wisconsin, as well as a B.S. in Biology from Rutgers University.
Thomas Ebeling currently serves as an MPM Advisor and is the former CEO of ProSiebenSat.1 Media SE and Novartis Pharma. He currently serves on the supervisory board of Bayer AG and as the Chairman of Sivantos (Hearing Aids), Apleona (Facility Managment) and Remagine Ventures (Media and E Commerce). He is also a former board member of Lonza AG.
Dr. Mitchell (Mitch) H. Finer is the CSO of ElevateBio, an MPM portfolio company, and President of ElevateBio BaseCamp. Mitch has been instrumental in founding, building and leading a number of MPM portfolio companies. He is the founder and former CEO of Oncorus (NASDAQ: ONCR), focused on the development of best-in-class oncolytic virus therapies for both local and systemic administration. He is also a founder and the former CEO of CODA Biotherapeutics, focused on developing a chemogenetic neuromodulation platform for the treatment of severe neurological disorders. Mitch serves on several MPM portfolio company boards, including CODA, ElevateBio and Oncorus.
Prior to joining MPM, he was the CSO of bluebird bio. For three decades, Mitch has focused on drug development utilizing the novel platforms of cell and gene therapy, cancer immunotherapy and regenerative medicine, and he has held several senior leadership roles in companies developing these therapies. He has also served as CEO of Intracel Corporation and Genteric, Vice President Research for Cell Genesys and the Gencell division of Aventis Pharma (now Sanofi) and Senior Vice President of Development at Novacell (now Viacyte). He also successfully co-founded a retinal disease gene therapy company Avalanche Biotechnologies (now Adverum Biotechnologies) where he serves as a member of the board of directors.
Mitch has been named inventor on 15 issued U.S. patents in the field of engineered proteins, cells and viruses in the fields of gene therapy of orphan disease, regenerative medicine and immune oncology. He received his Ph.D. in Biochemistry and Molecular Biology from Harvard University and a B.S. in Biochemistry and Microbiology from the University of California at Berkeley. He completed a post-doctoral fellowship at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology.
Dr. Briggs W. Morrison is the CEO and a Board Director of Syndax Pharmaceuticals (NASDAQ: SNDX), an MPM portfolio company. Briggs serves on the board of MPM portfolio companies Oncorus (NASDAQ: ONCR), Repare Therapeutics (NASDAQ: RPTX), Twentyeight-Seven Therapeutics and Werewolf Therapeutics. Briggs is also an investment committee member of the UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both private and public equities) managed by MPM.
Prior to joining MPM, Briggs served as Chief Medical Officer and Executive Vice President for Global Medicines Development at AstraZeneca. His career also includes distinguished roles at Pfizer and Merck. As Head of Global Medicines Development at AstraZeneca, he oversaw all clinical development functions and late-stage clinical development projects. As Head of Clinical Development at Pfizer, he oversaw Phase 1-3 development and operations for all therapeutic areas before being appointed the Head of Development, Medical Affairs, Safety and Regulatory Affairs for all Pfizer human health businesses. Briggs has overseen the development of numerous biopharmaceutical products in multiple therapeutic areas, such as LYMPARZA® and TAGRISSO®. He was also the former Chairman of Transcelerate BioPharma, an industry-funded company charged with improving aspects of clinical trials.
Briggs earned his M.D. from the University of Connecticut and completed his training in Internal Medicine at Massachusetts General Hospital and in Medical Oncology at the Dana-Farber Cancer Institute. He also completed a post-doctoral research fellowship in the Department of Genetics at Harvard Medical School and additional post-doctoral work at the Dana-Farber Cancer Institute. He received his B.S. in Biology from Georgetown University.
Dr. Greg Sieczkiewicz serves as Chief IP Counsel for several MPM portfolio companies including iTeos Therapeutics (NASDAQ: ITOS), Orna Therapeutics, and Werewolf Therapeutics, and as an IP advisor to several additional MPM portfolio companies.
Prior to joining MPM, Greg was the IP strategy architect for more than a dozen venture-backed life sciences companies across the spectrum—from nucleic acid therapeutics, oral biologics and the microbiome to oncology and protein engineering. He has served as Vice President, IP at Flagship Ventures, and also practiced patent counseling and enforcement at national law firms Mintz Levin, Proskauer Rose and Foley Hoag. Greg is a member of the bar of the Commonwealth of Massachusetts and is admitted to practice before the U.S. Patent and Trademark Office. He is also the former President of the Boston Patent Law Association.
Greg received his J.D., magna cum laude, from the evening program of Suffolk University Law School and earned his Ph.D. in Cell, Molecular and Developmental Biology from Tufts University School of Medicine and completed his post-doctoral fellowship at the National Cancer Institute. He received his A.B. in Biology from the College of the Holy Cross.
Dr. Patrick A. Baeuerle is the co-founder of six MPM oncology portfolio companies including Harpoon Therapeutics (NASDAQ: HARP), iOmx Therapeutics, Maverick Therapeutics, TCR² Therapeutics (NASDAQ: TCRR), Werewolf Therapeutics and Cullinan Oncology, where he is the CSO of Biologics. Patrick serves on the board of directors of iOmx and TCR² and is an investment committee member of the UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both private and public equities) managed by MPM.
Prior to joining MPM as an Executive Partner in 2015, Patrick served as Vice President of Research and General Manager of Amgen Research Munich GmbH and as CSO for Micromet, where he was responsible for the development of BiTE antibody Blincyto®, which was approved by the U.S. FDA in 2014 in less than three months as a therapy for relapsed/refractory acute lymphoblastic leukemia. He earlier headed small-molecule drug discovery at Tularik, a publicly traded biotechnology company acquired by Amgen. Prior to this, he was Professor and Chairman of Biochemistry and Molecular Biology at the Medical Faculty of Freiburg University, Germany, where he did groundbreaking research on transcription factor NF-kappaB.
Patrick is the recipient of Xconomy’s 2019 “X of the Year Award”, and the European Molecular Biology Laboratory’s 2019 Lennart Philipson Award in recognition of his many contributions to the development of cancer immunotherapies. To date, he has published 243 PubMed-listed papers that have been cited more than 75,000 times. He has a Hirsch index of 133 and was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990 to 1997).
Patrick holds a Ph.D. in Biology from the University of Munich (LMU) and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty of LMU in Munich, Germany.
Dr. Elizabeth (Liz) Stoner is the Senior Clinical Advisor of AlloVir (NASDAQ: ALVR), an ElevateBio company, and was most recently the company’s interim CMO. She also serves as Senior Clinical Advisor to Rhythm Pharmaceuticals (NASDAQ: RYTM). Liz is a distinguished biopharma executive, who brings decades of international industry experience to her role guiding and growing MPM portfolio companies.
Liz has held several leadership roles at MPM portfolio companies including interim CEO of Semma Therapeutics; founder, CMO and Chief Development Officer (CDO) of Rhythm and the CDO of Vascular Pharmaceuticals. She also served in clinical and advisory roles at Clinical Ink, Potenza Therapeutics, Solasia and TriNetX. Liz is a member of the Cures Acceleration Network Review Board of the National Center for Advisory Translations Sciences of the NIH to represent viewpoints of drug development and venture capital professionals regarding the discovery and development of therapeutics, diagnostics and devices.
Prior to joining MPM, Liz was Senior Vice President of Global Clinical Development Operations at Merck Research Laboratories where she was responsible for its clinical development activities in more than 40 countries. While at Merck, she also oversaw the clinical development activities of its Japanese subsidiary and played a leading role in Merck/Schering Plough Joint Venture’s development of Vytorin and Zetia, blockbuster cholesterol lowering drugs. Previously, she led the 5-alpha reductase clinical development program, establishing Merck as a leader in the field of prostate disease. As Endocrine Therapeutic Head at Merck, her responsibilities included all steroid and lipid metabolism, as well as the bisphosphonate and growth hormone secretagogue clinical research programs. Prior to joining the biopharma industry, she was an Assistant Professor of Pediatrics at Cornell University Medical College. Liz currently serves on the boards of Vascular Pharmaceuticals and Momenta Pharmaceuticals. She is also a member of the Albert Einstein College of Medicine Board of Governors, and the Weill Cornell Medical College Clinical and Translational Science Center External Advisory Board.
Liz received her M.D. from the Albert Einstein College of Medicine, her M.S. in Chemistry from SUNY at Stony Brook and her B.S. in Chemistry from Ottawa University, KS.
Dr. Gary Patou currently serves as an MPM Advisor and Chief Medical Officer (CMO) at Blade Therapeutics and Head of Clinical at Chiasma, both MPM portfolio companies. He has also previously served as CMO at various MPM portfolio companies, including Pacira Pharmaceuticals, Peplin and True North Therapeutics. He played a leading role in gaining FDA approvals for both Pacira’s EXPAREL™ and Peplin’s PICATO™.
Prior to joining MPM, Gary was Executive Vice President and CMO of Oscient Pharmaceuticals, following its merger with GeneSoft Pharmaceuticals. As President of GeneSoft, he was instrumental in applying for and obtaining FDA approval of the company’s lead product, FACTIVE®. Before GeneSoft, Gary worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline, as Senior Vice President and Director, Project and Portfolio Management, managing all of the company’s pharmaceutical development projects including FACTIVE®, as well as FDA-approved products Paxil® and Augmentin®. Prior to this, he served as Director and Vice President of Anti-Infective Development and managed the development of a broad line of anti-infective products. Gary has held several academic appointments at University College and Middlesex School of Medicine in London and is a member of the University of California, San Francisco Clinical and Translational Science Institute Catalyst Program.
Gary received his Medical and Medical Ph.D. degrees from University College, London.
Dr. Dan Hicklin currently serves as an MPM Advisor and is Founder and CEO of Werewolf Therapeutics, an MPM portfolio company. Dan is an accomplished cancer researcher and biopharmaceutical executive with over three decades of oncology drug development experience. He also serves as President of Trieza Therapeutics and is a board member of Harpoon Therapeutics, Tizona Therapeutics and Maverick Therapeutics, and is on the scientific advisory board of Oncorus (NASDAQ: ONCR). Most recently, Dan was Founder, President and CEO of Potenza Therapeutics (acquired by Astellas Pharma) and President and Chief Scientific Officer of CoStim Pharmaceuticals (acquired by Novartis).
Prior to joining MPM, Dan held several positions at Merck Research Laboratories (formerly the Schering-Plough Research Institute prior to its acquisition by Merck), including leading their Biologics Strategy for Oncology and the Immuno-Modulation Discovery team. In these roles, he oversaw several oncology discovery and development projects including Merck’s immuno-oncology portfolio and the development of Keytruda® (pembrolizumab). Prior to joining Schering-Plough, Dan held several positions of increasing responsibility at ImClone Systems (acquired by Eli Lilly), including serving as Vice President of Experimental Therapeutics. His team at ImClone supported the development and FDA approval of the cancer treatment Erbitux® (cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), Portrazza® (necitumumab), Lartruvo® (olaratumab) and other agents that were acquired by Eli Lilly.
Dan holds an M.S. and Ph.D. in Immunology from New York Medical College where he trained with Dr. Soldano Ferrone, and his B.S. from the University of Iowa.
Dr. William (Bill) Greene currently serves as an MPM Advisor and CEO of Iconic Therapeutics, an MPM portfolio company, which is developing novel therapeutics for ophthalmologic diseases and cancer. Bill is an experienced biotechnology executive and investor in biopharmaceuticals and medical devices.
Bill’s board and investment experience includes Alnara (acquired by Eli Lilly), Alsius (Acquired, Zoll), Barrier Therapeutics (BTRX), Cotherix (acquired by Actelion), Idun Pharmaceuticals (acquired by Pfizer) and Intercell AG (ICLL). In addition to investing and serving on corporate boards, Bill has filled roles on MPM portfolio companies including interim Vice President of Regulatory Affairs, and Chief Medical Officer. Prior to joining MPM, Bill was at Genentech (acquired by Roche) where he served as a Senior Clinical Scientist and Epidemiologist with responsibilities in clinical strategy, trial design and regulatory affairs in several therapeutic areas across all phases of drug development from translational research through post-marketing studies. Among products whose clinical development he led or participated in are Lucentis, Avastin, and Raptiva. Prior to Genentech, Bill was at Yale Medical School where he studied, taught, and performed clinical research in Internal Medicine and Diagnostic Radiology. He has also been an Assistant Clinical Professor of Medicine at the University of California, San Francisco and was an active member of the teaching staff at San Francisco General Hospital.
In addition to his work with MPM, Bill’s passion for using biotechnology to address significant unmet human needs extends to global health. He is an advisor to the Bill and Melinda Gates Foundation and was Chairman of the Board and head of the Investment Committee of the Global Health Investment Fund, a pioneering initiative supported by the Foundation that brings together investors, philanthropists and industry to forge creative solutions to bring the fruits of biotechnology to the underserved around the world.
Bill received his M.D. from the University of California, San Francisco and has been a Robert Wood Johnson Clinical Scholar at Yale (clinical epidemiology) and a Howard Hughes Medical Institute Research Scholar at the NIH (neurobiology). He earned his B.A. degree from Wesleyan University.